Skip to Main Content
Home
Search
Study Topics
Glossary
Full Text View
Tabular View
No Study Results Posted
Related Studies
Treatment of Acyclovir-Resistant Mucocutaneous Herpes Simplex Disease in Patients With AIDS: Open Label Pilot Study of Topical Trifluridine
This study has been completed.
Study NCT00000635 Information provided by National Institute of Allergy and Infectious Diseases (NIAID)
First Received: November 2, 1999 Last Updated: June 23, 2005
History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Herpes Simplex
HIV Infections
Additional conditions recognized in this trial
Acquired Immunodeficiency Syndrome
Communicable Diseases
Infection
More general conditions related to this trial
DNA Virus Infections
Herpesviridae Infections
Immune System Diseases
Immunologic Deficiency Syndromes
Lentivirus Infections
Retroviridae Infections
RNA Virus Infections
Sexually Transmitted Diseases
Sexually Transmitted Diseases, Viral
Skin Diseases
Skin Diseases, Infectious
Skin Diseases, Viral
Slow Virus Diseases
Virus Diseases
Interventions listed in this trial
Trifluridine
Bacitracin zinc/Polymyxin B sulfate
Additional drug interventions recognized in this trial
Anti-Infective Agents, Local
Bacitracin
Polymyxin B
Polymyxins
More general drug interventions related to this trial
Anti-Bacterial Agents
Anti-Infective Agents
Antimetabolites
Antiviral Agents
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Therapeutic Uses
Sponsors listed in this trial
National Institute of Allergy and Infectious Diseases (NIAID)
Glaxo Wellcome
Back to top of Main Content
